Table 2.

Multivariable analysis of (a) DFS, (b) OS and (c) pCR (binary logistic) according to patients and treatment characteristics.

(a) DFS
Variables		HR	95% CI	p-value
Tumor biology	TNBC versus HR+ BC	1.81	1.07–3.09	0.028
Primary tumor	cT3–cT4 versus cT1–cT2	0.98	0.5–1.91	0.959
Axillar nodes	cN1–3 versus cN0	1.13	0.66–1.93	0.656
ChT regimen	AT×3 CMF×3 versus AT×4 CMF×4	0.85	0.50–1.63	0.717
(b) OS
Variables		HR	95% CI	p-value
Tumor biology	TNBC versus HR+ BC	16.86	3.62–78.4	0.003
Primary tumor	cT3–cT4 versus cT1–cT2	0.46	0.13–1.70	0.245
Axillar nodes	cN1–3 versus cN0	0.72	0.36–1.44	0.075
No. of treatment cycles	AT×3 CMF×3 versus AT×4 CMF×4	4.31	0.86–21.7	0.075
(c) pCR
Variables		OR	95% CI	p-value
Tumor biology	TNBC versus HR+ BC	2.61	1.32–5.17	0.0595
Primary tumor	cT3–cT4 versus cT1–cT2	0.98	0.45–2.13	0.966
Axillar nodes	cN1–3 versus cN0	0.72	0.36–1.44	0.355
No. of treatment cycles	AT×3 CMF×3 versus AT×4 CMF×4	0.98	0.48–1.98	0.941

The p-value of the multivariable analysis for each characteristic is indicated in the right column of the table. The p-value of the test is indicated in bold numbers when statistically significant.

AT, doxorubicin-paclitaxel; CI, confidence interval; CMF, cyclophosphamide-methotrexate-5-fluorouracil; DFS, disease free survival; HR, hazard ratio; HR+ BC: hormone receptor-positive breast cancer; OS, overall survival; pCR, pathologic complete response; TNBC, triple-negative breast cancer.